BLOG

opthalmology times

Safety data for at-home subcutaneous injection option for treatment of wet AMD, DME

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.